Transactions

Biogen, Inc.’s sale of its 49.9% stake in Samsung Bioepis to Samsung Biologics

Date Announced:
01/27/2022

client:
Biogen, Inc.

Status:
Closed – 04/20/2022

Value:
$2.3 billion